Hormonal
Pre-existing use of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) is significantly associated with reduced weight loss in patients undergoing a Full Meal Replacement (FMR) intensive lifestyle intervention.
If you are currently taking a GLP-1 RA (like Ozempic or Wegovy) and start a strict meal replacement program, you might not lose as much weight as expected compared to those not on the medication. This does not mean the medication is ineffective, but its interaction with the FMR protocol may differ from standard expectations. Discuss this with your provider.
Patients on a Glucagon‐like Peptide‐1 Receptor Agonist prior lost less weight.
Why this rating
Retrospective cohort study; association does not prove causation.
Source
A comparison of virtual and in person delivery of a full meal replacement program for obesity
Matthew Skeldon et al. · Obesity Science & Practice · 2023
DOI 10.1002/osp4.718
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →